STOCK TITAN

RSU dividend adds 201 shares for DENTSPLY (NASDAQ: XRAY) director

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

DENTSPLY SIRONA Inc. director Willie A. Deese reported an automatic stock-related transaction. On 01/09/2026, he acquired 201.508 shares of common stock at a price of $0. These shares represent dividends on previously granted restricted stock units (RSUs), paid in the form of additional RSUs that carry the same vesting schedule as the original awards.

Following this transaction, Deese directly beneficially owned 57,748.066 shares of DENTSPLY SIRONA common stock. Each RSU converts into one share of common stock on a 1:1 basis, and the dividend RSUs vest at the same time as the underlying RSUs they relate to.

Positive

  • None.

Negative

  • None.
Insider Deese Willie A
Role Director
Type Security Shares Price Value
Grant/Award Common Stock 201.508 $0.00 --
Holdings After Transaction: Common Stock — 57,748.066 shares (Direct)
Footnotes (1)
  1. [object Object]
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Deese Willie A

(Last) (First) (Middle)
C/O DENTSPLY SIRONA INC
13320-B BALLANTYNE CORPORATE PLACE

(Street)
CHARLOTTE NC 28277

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
DENTSPLY SIRONA Inc. [ XRAY ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
01/09/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/09/2026 A 201.508(1) A $0 57,748.066 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents dividends on restricted stock units (RSUs) awarded to the Reporting Person in the form of additional RSUs and are subject to the same vesting terms as the underlying awards. The dividends vest simultaneously with the RSUs to which they relate. Each RSU converts to common stock on a 1:1 basis.
/s/ Jessica Nielsen Causey, Attorney-in-Fact for Willie A. Deese 01/13/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did DENTSPLY SIRONA (XRAY) director Willie A. Deese report on this Form 4?

The filing shows that director Willie A. Deese acquired 201.508 shares of DENTSPLY SIRONA common stock on 01/09/2026, at a price of $0 per share.

Why did Willie A. Deese receive 201.508 DENTSPLY SIRONA (XRAY) shares?

The 201.508 shares represent dividends on restricted stock units (RSUs), paid in the form of additional RSUs. These dividend RSUs follow the same vesting terms as the underlying RSU awards.

How many DENTSPLY SIRONA (XRAY) shares does Willie A. Deese own after this transaction?

After the reported transaction, Willie A. Deese beneficially owned 57,748.066 shares of DENTSPLY SIRONA common stock in direct ownership.

What is the vesting treatment of the RSU dividend shares for DENTSPLY SIRONA (XRAY)?

The dividend RSUs are subject to the same vesting terms as the underlying RSU awards, and the dividends vest simultaneously with those original RSUs.

How do the RSUs reported by DENTSPLY SIRONA (XRAY) director convert into common stock?

Each restricted stock unit (RSU), including the dividend RSUs, converts into one share of common stock on a 1:1 basis when it vests.

Is this DENTSPLY SIRONA (XRAY) Form 4 transaction a market purchase or sale?

No market trade is indicated. The Form 4 shows an "A" (acquisition) code at a $0 price, reflecting stock-based compensation in the form of RSU dividends, not an open-market buy or sell.